M&G PLC Takes Position in Krystal Biotech, Inc. $KRYS

M&G PLC acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,748 shares of the company’s stock, valued at approximately $924,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KRYS. State of New Jersey Common Pension Fund D lifted its stake in shares of Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock valued at $2,066,000 after purchasing an additional 4,682 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Krystal Biotech during the first quarter worth $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after buying an additional 365,304 shares in the last quarter. S Squared Technology LLC lifted its position in shares of Krystal Biotech by 2.1% in the first quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock worth $17,528,000 after buying an additional 2,000 shares during the last quarter. Finally, Tempus Wealth Planning LLC acquired a new stake in shares of Krystal Biotech in the second quarter worth about $327,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.9%

Shares of KRYS stock opened at $201.21 on Friday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $212.98. The firm has a market cap of $5.84 billion, a PE ratio of 30.17 and a beta of 0.65. The stock has a 50 day moving average of $178.76 and a 200-day moving average of $155.00.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of a number of analyst reports. Bank of America increased their price objective on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Citigroup increased their price target on Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Monday, September 15th. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $228.14.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).